NasdaqGM:MAZEPharmaceuticals
Maze Therapeutics (MAZE) Rebounds This Week, Is The Upside Already Priced In?
Maze Therapeutics (MAZE) has attracted attention after recent trading performance. The stock is up 5.2% in the past day and 10.7% over the past week, prompting fresh interest in its clinical pipeline.
See our latest analysis for Maze Therapeutics.
Zooming out, Maze Therapeutics has a 30 day share price return of 9.14%, although the share price is down 28.51% year to date, while the 1 year total shareholder return of 134.38% indicates a notable rebound in sentiment and risk appetite around its...